Lu Zhou, PhD, of the University of Plymouth, UK, publishes article “The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors” in the peer-reviewed journal Oncogene. This work was in part supported by a Children’s Tumor Foundation Young Investigator Award in 2013, and was based on the need for effective, safe treatments for NF2-specific schwannomas.
Zhou and his team focused on a so-called scaffold protein, KSR1, a protein that binds together within the cell to perform specific biochemical functions. Through research done in vitro, it became apparent that this protein plays a key role in schwannoma development, which suggests that it could be a key therapeutic target for NF2 schwannomas.
Click here for the article preview on the publication’s website.
